Cipro Xr is a drug owned by Bayer Healthcare Pharmaceuticals Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 23, 2021. Details of Cipro Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US8187632 (Pediatric) | Sustained-release preparations of quinolone antibiotics |
Dec, 2021
(2 years ago) |
Expired
|
|
US7709022 (Pediatric) | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
Dec, 2021
(2 years ago) |
Expired
|
| US7709022 | Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
Jun, 2021
(3 years ago) |
Expired
|
| US8187632 | Sustained-release preparations of quinolone antibiotics |
Jun, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cipro Xr's patents.
Latest Legal Activities on Cipro Xr's Patents
Given below is the list of recent legal activities going on the following patents of Cipro Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 01 Jul, 2024 | US8187632 |
| Maintenance Fee Reminder Mailed Critical | 15 Jan, 2024 | US8187632 |
| Expire Patent Critical | 06 Jun, 2022 | US7709022 |
| Maintenance Fee Reminder Mailed Critical | 20 Dec, 2021 | US7709022 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Nov, 2019 | US8187632 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Oct, 2017 | US7709022 |
| Post Issue Communication - Certificate of Correction | 21 Feb, 2013 | US8187632 |
| Recordation of Patent Grant Mailed Critical | 29 May, 2012 | US8187632 |
| Patent Issue Date Used in PTA Calculation Critical | 29 May, 2012 | US8187632 |
| Issue Notification Mailed Critical | 09 May, 2012 | US8187632 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Cipro Xr and ongoing litigations to help you estimate the early arrival of Cipro Xr generic.
Cipro Xr's Litigations
Cipro Xr been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 15, 2010, against patent number US8187632. The petitioner , challenged the validity of this patent, with Venkata-Rangarao Kanikanti et al as the respondent. Click below to track the latest information on how companies are challenging Cipro Xr's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8187632 | June, 2010 |
Decision
(08 Nov, 2011) | Venkata-Rangarao Kanikanti et al | |
US patents provide insights into the exclusivity only within the United States, but Cipro Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cipro Xr's family patents as well as insights into ongoing legal events on those patents.
Cipro Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cipro Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 23, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cipro Xr Generic API suppliers:
Ciprofloxacin; Ciprofloxacin Hydrochloride is the generic name for the brand Cipro Xr. 6 different companies have already filed for the generic of Cipro Xr, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cipro Xr's generic
About Cipro Xr
Cipro Xr is a drug owned by Bayer Healthcare Pharmaceuticals Inc. Cipro Xr uses Ciprofloxacin; Ciprofloxacin Hydrochloride as an active ingredient. Cipro Xr was launched by Bayer Hlthcare in 2002.
Approval Date:
Cipro Xr was approved by FDA for market use on 13 December, 2002.
Active Ingredient:
Cipro Xr uses Ciprofloxacin; Ciprofloxacin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Ciprofloxacin; Ciprofloxacin Hydrochloride ingredient
Dosage:
Cipro Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 425.2MG;EQ 574.9MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE | Discontinued | ORAL |
| 212.6MG;EQ 287.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, EXTENDED RELEASE | Discontinued | ORAL |